Cyara Accelerates Growth With Senior Global Appointments
16.11.2022 00:00:00 EET | Business Wire | Press release
Cyara, provider of the leading Automated Customer Experience (CX) Assurance Platform, has appointed Max Lipovetsky to the role of VP Products and Russ Hellmann to VP Growth Marketing, as it accelerates its global foothold.
With over 20 years’ experience in the contact centre and IVR industry, Max Lipovetsky brings a wealth of knowledge as Cyara’s VP Products. In 2003, Max co-founded Global Speech Networks and brought to market one of the first SaaS contact centre clouds - capturing the attention of some of ANZ’s largest businesses. Based in Melbourne, Australia, Max will be instrumental in guiding Cyara through its next stage of product innovation, including the fast-evolving role of AI in testing.
Russ Hellmann, Fujitsu’s former Head of Global Demand - Digital Innovation, joins Cyara in the newly created role of VP Growth Marketing. Based in Texas, US, he will be responsible for developing a centralised capability for regional teams that will enable customer acquisition and partner activation. Russ will lead four strategic pillars of growth - Global Programmes, Digital Marketing, Field Marketing and Partner Marketing - which, together, will play an influential role in planning, building and activating campaigns that will enable Cyara to scale at speed.
These two significant additions to Cyara’s senior team follow last month’s appointments of Dean Saunders, Channel and Alliances Director of APAC, and Vikram Verma, Cyara’s first independent board member.
Max Lipovetsky, VP Products, said, “Cyara brings agility and accelerated innovation to CX, turbo-charging businesses that are driven to create the best possible experiences for their customers. Cyara does this through CX Assurance; a product category it has created almost single-handedly on a global scale. With its history of innovation and an organisational platform built for growth I’m incredibly excited to be joining Alok and the team.”
Russ Hellmann, VP Growth Marketing, said, “CX is both an art and a science - and only Cyara can measure, test and optimize for both. As the rapid and fundamental shift to the cloud continues, ensuring every facet of the CX journey is seamless has become paramount for success. With Cyara’s comprehensive assurance capabilities, expansive global partnerships and passionate people, I’m thrilled to be joining a fast-growing category leader that is pushing and redefining boundaries.”
Alok Kulkarni, CEO and Co-Founder of Cyara, added, “Securing talent like Max and Russ to help drive our product innovation, value proposition and growth strategy, places Cyara in a very unique, and fortunate position as we head into 2023. We are entering a period of massive disruption within our industry which will create risks and opportunities along the way. From our growth ambitions to our employee happiness, ensuring we have the right leaders in place is vital and I can’t wait to see the impact both Russ and Max will create for customers, partners and the team.”
About Cyara
Cyara is the world’s leading Automated Customer Experience (CX) Assurance platform, headquartered in Silicon Valley. Cyara’s cloud-based omnichannel assurance solutions for voice quality and chatbot testing accelerate the delivery of flawless customer journeys for enterprises while reducing the risk of customer-facing defects. Every day, major global brands trust the Cyara Platform to deliver customer smiles at scale. For more information, please visit cyara.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20221115005525/en/
Contact information
Diana Gallagher
(408) 656-9699
10Fold Communications for Cyara
cyara@10fold.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Datavault AI Announces Board of Directors Has Requested Management’s Complete Plan for Dividend Spin-Out of Acoustic Sciences Division into Stand-Alone Public Company7.5.2026 16:07:00 EEST | Press release
Datavault AI Inc. (“Datavault AI” or the “Company”) (NASDAQ:DVLT), a pioneering technology licensing company seeking to redefine data valuation, monetization, and secure Web 3.0 experiences, today announced that Company management has commenced its evaluation of a potential dividend spin-out of the Company’s Acoustic Sciences division which includes its ADIO®, WiSA®, Event Citadel™, and API Media operations into a new stand-alone public company, which is proposed to be named “API Media”. The Company has reserved the ticker symbol “ADIO” for the proposed spin-out entity and currently intends that API Media will be listed on NASDAQ following completion of the proposed transactions, which remain subject to approval by the Company’s board of directors, definitive agreement, and satisfaction of closing conditions, as well as any regulatory approvals that may be required in connection therewith. The Company has engaged Houlihan Lokey as its financial advisor and Paul Hastings LLP as its lega
Incyte Announces 24-Week Long-Term Data from Phase 3 TRuE-AD4 Trial of Opzelura ® (ruxolitinib) Cream in Adults with Moderate Atopic Dermatitis7.5.2026 15:50:00 EEST | Press release
Incyte (Nasdaq:INCY) today announced final 24-week data from the Phase 3 TRuE-AD4 study evaluating the efficacy and safety of Opzelura® (ruxolitinib) cream in adults with moderate atopic dermatitis (AD) who had an inadequate response, intolerance or contraindication to topical corticosteroids (TCSs) and topical calcineurin inhibitors (TCIs). These data were presented (Abstract ID: P0851) today at the 2026 European Academy of Dermatology and Venereology (EADV) Symposium, being held May 7–9, 2026, in Athens, Greece. As previously reported, the TRuE-AD4 study met both of its co-primary endpoints at Week 8, with a statistically significantly higher proportion of patients on Opzelura versus vehicle cream achieving EASI75 (≥75% improvement in Eczema Area and Severity Index score from baseline) and, separately, IGA-TS (Investigator's Global Assessment Treatment Success, defined as an IGA score of 0 [clear] or 1 [almost clear] with at least a two-point improvement from baseline).1 Patients who
Rapid Medical™’s TIGERTRIEVER™ 13 Demonstrates Promising 90-Day Outcomes in DISTALS Trial, Reinforcing Pivotal Safety and Efficacy Findings7.5.2026 15:03:00 EEST | Press release
Rapid Medical™, a leading developer of advanced stroke treatment devices, today announced full results from the DISTALS randomized clinical trial, presented at the 11th European Stroke Organisation Conference (ESOC) in Maastricht, Netherlands, showing that TIGERTRIEVER™ 13 can safely restore blood flow to the brain and may improve clinical outcomes in patients with distal and medium vessel occlusion (DMVO) stroke. These findings build on earlier results showing a threefold improvement in restoring blood flow compared with medical management alone (p<0.0001), with no cases of serious brain bleeding observed in the treatment group. “These results show we can now safely restore blood flow and suggest this will make a meaningful difference for the right patients,” said Jeffrey L. Saver, MD, UCLA, and Principal Investigator of DISTALS. “What’s important is that both the device and the trial were designed specifically for distal stroke. By using a device built for these small vessels and mea
2 Million Downloads in Six Months: Tabelog’s Multilingual App Solves Critical Dining Pain Points for Travelers to Japan7.5.2026 15:00:00 EEST | Press release
Tabelog (https://tabelog.com/en/), one of Japan’s largest (*1) restaurant search and reservation services operated by Kakaku.com, Inc., has announced that its multilingual smartphone app (iOS/Android) for travelers visiting Japan has reached 2 million downloads (*2). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260507560248/en/ 2M+ Downloads in 6 Months. The app also ranked #1 in downloads among Restaurant Search Apps in Japan for International Travelers (*3) in Taiwan, Hong Kong, South Korea, and the U.S., reflecting its immense popularity among global visitors. Download URL: https://tabelog-tourists.onelink.me/3eEh/iqkkho9r The Trusted Choice for Global Travelers: Solving Two Major Dining Pain Points in Japan For years, international visitors to Japan have faced two critical dining pain points: [Pain Point 1] The Information Gap: Most available resources are tailored for tourists, making it difficult to find the true loc
Altasciences and Certara Announce Strategic Partnership to Accelerate Early Drug Development7.5.2026 15:00:00 EEST | Press release
Altasciences, a fully integrated drug development solution company, andCertara (Nasdaq: CERT), a global leader in model-informed drug development (MIDD), today announced a strategic partnership to accelerate early-phase development programs. Fewer than half of preclinical drug candidates successfully reach first-in-human trials. Failures are driven by toxicity, poor pharmacokinetics, lack of efficacy, and challenges translating results from animals to humans. Many of these risks can be mitigated through a fully integrated model-informed drug development approach. Building on Altasciences’ Acceleration Platform, the integration of Certara’s strategic drug development services and biosimulation technology enables sponsors to establish proof of mechanism earlier, design more efficient studies, and make informed go/no-go decisions with greater confidence. By embedding modeling insights and digital workflows directly into development execution, study designs are optimized, dosing strategies
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
